コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nregulates transforming growth factor beta2 (TGF-beta2).
2 to SPARC, does not appear to be regulated by TGF-beta2.
3 required for regulation of FLT3 signaling by TGF-beta2.
4 , through the Akt-mediated downregulation of TGF-beta2.
5 ated with thrombin TNF-alpha, monocytes, and TGF-beta2.
6 ession of furin and downstream TGF-beta1 and TGF-beta2.
7 tion in SP cells of ABCG2, Sca-1, Wnt-1, and TGF-beta2.
8 ctors-vascular endothelial growth factor and TGF-beta2.
9 f hematopoietic stem and progenitor cells to TGF-beta2.
10 ge in either gene or protein expression with TGF-beta2.
11 tly tested the ability of TbetaRII-B to bind TGF-beta2.
12 ed more robust changes than those induced by TGF-beta2.
13 iinflammatory myeloid cells via secretion of TGF-beta2.
14 wn targets, transcription factors ZEB1/2 and TGF-beta2.
15 uced by platelet-derived growth factor-BB or TGF-beta2.
16 while upregulation of SPARC had no effect on TGF-beta2.
17 don differentiation is partially mediated by TGF-beta2.
18 fetal lenses were cultured and treated with TGF-beta2 (1 or 10 ng/mL), FGF-2 (20 or 50 ng/mL), HGF (
19 rowth-factor reduced Matrigel also inhibited TGF-beta2; (2) independent matrix components, as the pur
20 in neurons, supporting a role for the CX3CL1-TGF-beta2/3-Smad2 pathway in the control of adult neurog
24 increased in Tgfb2+/- mice, suggesting that TGF-beta2 affects the earliest stages of T-cell developm
26 Thus, pregnancy-associated MaSCs require a TGF-beta2/alphavbeta3/Slug pathway, which may contribute
27 identified transforming growth factor-beta2 (TGF-beta2), an isoform of the TGF-beta family, as a mole
28 tured in the presence or absence of 10 ng/mL TGF-beta2 and 20 mug/mL recombinant human SPARC (rhSP) f
29 Taken together, our data suggest a role for TGF-beta2 and as yet unknown serum factors in the aging
32 the factors that regulate the processing of TGF-beta2 and extracellular matrix (ECM) proteins into t
34 lin by TM cells inhibits BMP-4 antagonism of TGF-beta2 and leads to increased ECM deposition and elev
36 profiling of the 5'-UPR of the genes, Gli1, TGF-beta2 and Msx2, responding to the Shh/Ptc1 signaling
38 esults identify the BG(ZP-C)-binding site on TGF-beta2 and shed light on the specificity of BG for se
39 ubjects' fibroblasts showed a lower level of TGF-beta2 and significantly increased the epithelial cel
41 rest cells results in elevated expression of TGF-beta2 and TGF-beta receptor type III (TbetaRIII); ac
43 correlates well with elevated expression of TGF-beta2 and TGF-beta3, and activation of their downstr
50 increased the C3 split products and the C9, TGF-beta2, and basic FGF levels in the retinal pigment e
55 the impact of IL-13 on epithelial TGF-beta1, TGF-beta2, and MUC5AC were determined in cultured bronch
57 ctive Akt blocked RES inhibition of CREB and TGF-beta2, and rescued RES inhibition of cellular invasi
58 promotes activation of pro-TGF-beta1 and pro-TGF-beta2, and TGF-beta2 in turn increases furin levels.
61 reased total and active levels of TGF-beta1, TGF-beta2, and TGF-beta3 that arise as a specific conseq
64 c) formed a high affinity complex that bound TGF-beta2, and this complex inhibited TGF-beta2 in a bio
65 cal differences in degree of PCO between the TGF-beta2- and FCS/PBS-treated groups at 3 and 14 days a
66 Nor were there differences between the anti-TGF-beta2- and the null antibody-treated groups, with th
67 S-treated control group), a human monoclonal TGF-beta2 antibody (anti-TGF-beta2-treated group), or a
68 nsforming growth factor (TGF)-beta2 and anti-TGF-beta2 antibody in a rodent model of posterior capsul
69 No sustained effect of TGF-beta2 or anti-TGF-beta2 antibody on PCO was found in rodents at the do
72 d transforming growth factor (TGF)-beta1 and TGF-beta2 as critical active soluble factors released by
73 Taken together, these observations identify TGF-beta2 as the crucial mediator of NPC immunomodulatio
74 ally, we found a novel role for dysregulated TGF-beta2, as well as adipocyte dysfunction, as demonstr
76 effect; or (3) inhibition of a constitutive TGF-beta2 autocrine feedback loop, as addition of exogen
80 ession of the cytokines TNF-alpha, IL-1beta, TGF-beta2, -beta3, and IL-10 and demonstrated defective
81 2.8 and 74.6 +/- 15.8 pm, respectively), but TGF-beta2 binding was undetectable at corresponding dose
82 xpress BMP1, BMP1 expression is regulated by TGF-beta2, BMP1 is biologically active, and BMP1 regulat
83 new disease framework whereby activation of TGF-beta2, bone morphogenetic protein 4, Wnt/beta-cateni
85 presence of unknown nonprotein serum factors TGF-beta2, but not TGF-beta1 or -beta3, enhances progeni
90 retion induced by thrombin and thrombin plus TGF-beta2 by 65% and 20%, respectively, but had no effec
92 ta suggest that stress induced production of TGF-beta2 by BEC can modify liver allograft function by
93 and also respond to application of exogenous TGF-beta2 by enhancing their endogenous TGF-beta2 expres
95 Exposure to RELM-beta increased TGF-beta1, TGF-beta2, collagen I, fibronectin, smooth muscle alpha-
99 of the papillary fibroblast lineage, whereas TGF-beta2 controls proliferation, differentiation and EC
100 al rats and test if a polymeric diet rich in TGF-beta2 could reduce TNBS-induced intestinal inflammat
103 demonstrated that Notch1 deficiency promotes Tgf-beta2 dependent M2-polarization in a mouse model of
111 l transplantation experiments indicated that TGF-beta2 expressed both in the (micro)environment and i
112 rsening in association with normalization of TGF-beta2 expression and high expression of TGF-beta1.
113 nous TGF-beta2 by enhancing their endogenous TGF-beta2 expression and their cell-matrix traction stre
114 evaluated bronchial epithelial TGF-beta1 and TGF-beta2 expression and their effects on mucin expressi
116 Quercetin down regulated TGF-betaR2 and TGF-beta2 expression in HKCs suggesting a significant li
119 B) transcription factor is known to regulate TGF-beta2 expression, and RES treatment decreased phosph
124 sforming growth factor-beta1 (TGF-beta1) and TGF-beta2, forcing these growth factors into a state of
125 ese findings indicate that Matrigel inhibits TGF-beta2 gene expression and point to a mechanism depen
131 o include Ser-112 and Lys-119, homologous to TGF-beta2 Ile-92 and Lys-97, on the inside of the finger
133 SHV microRNAs are sufficient to downregulate TGF-beta2 in endothelial cells, they are not required du
134 ere asthmatics' fibroblasts induced enhanced TGF-beta2 in exosomes leading to a reduced proliferation
136 ults suggest a new functional requirement of TGF-beta2 in growth arrest and differentiation of murine
138 cin expression, and the role of TGF-beta1 or TGF-beta2 in interleukin (IL)-13-induced mucin expressio
146 of active transforming growth factor-beta2 (TGF-beta2) in the aqueous humor is the main cause of fib
147 ment of mitral valve interstitial cells with TGF-beta2 increased beta-catenin signaling at mRNA and p
149 rine feedback loop, as addition of exogenous TGF-beta2 increased p-Smad3 and restored TGF-beta2 mRNA
152 Although the incubation of TM cells with TGF-beta2 induced miR-29a and suppressed miR-29b levels,
154 nd inhibits transforming growth factor-beta2(TGF-beta2)-induced EMT of RPE cells by deacetylating SMA
161 podocytes, it is demonstrated that autocrine TGF-beta2 induces G0/G1 arrest and differentiation under
165 tent infection, as the addition of exogenous TGF-beta2 inhibits the KSHV-induced stability of these s
166 sive bleb aqueous and controls in the amount TGF-beta2, interleukins IL-6, IL-10, and chemokine (C-X-
168 an in wild-type littermates, indicating that TGF-beta2 is a genetically determined positive regulator
170 TM cells were treated with TGF-beta2 because TGF-beta2 is associated with primary open-angle glaucoma
171 , we found that the BG(ZP-C)-binding site on TGF-beta2 is located on the inner surface of its extende
172 ously that transforming growth factor-beta2 (TGF-beta2) is a genetically determined positive regulato
173 previously shown that one TGF-beta isoform, TGF-beta2, is, in fact, a positive regulator of murine h
175 pecimens negatively correlates with WNT7B or TGF-beta2 level and is significantly associated with poo
177 ations or deletions in the gene encoding the TGF-beta2 ligand for a phenotype within the LDS spectrum
179 in the TM and suggest that its modulation by TGF-beta2 may be important in controlling ECM synthesis.
181 F, GRO, MIP-1beta, IL-1alpha, TGF-beta1, and TGF-beta2 may play a significant role in regulating inva
184 ubjects had increased circulating TGF-beta1, TGF-beta2, monocyte chemotactic protein-1, C-reactive pr
185 Importantly, miR-21 overexpression increased TGF-beta2 mRNA and secreted protein level, consistent wi
188 When exposed to recombinant TGF-beta1 (or TGF-beta2), nonpermissive culture podocytes switch to G2
189 nificant non-overlapping phenotypes with the TGF-beta2 null mouse, implying the existence of TbetaRII
190 nown about the impact of either TGF-beta1 or TGF-beta2 on asthmatic airway epithelial mucin expressio
193 can be attributed to the enhancing effect of TGF-beta2 on HSPC proliferation observed in vitro and ar
197 EC (but not HMEC-1) upregulate expression of TGF-beta2 on stiffer matrices, and also respond to appli
198 udy we report that the stimulatory effect of TGF-beta2 on the proliferation of LSK cells increases wi
201 aneous mRNA expression of TGF-beta1, but not TGF-beta2 or TGF-beta3, and elevated C-C chemokines macr
202 tivity was measured in TM cells treated with TGF-beta2 or with a combination of TGF-beta2/UK383367.
203 he ligands transforming growth factor-beta2 (TGF-beta2) or bone morphogenetic protein-4 (BMP4) in an
206 kers, and increased TGF-beta1 (P=0.0009) and TGF-beta2 (P=0.0001) secretion in dermal fibroblast cell
207 e found elevated plasma TGF-beta1 (P=0.009), TGF-beta2 (P=0.004) and additional inflammatory markers,
208 on of key pro-fibrogenic factors, TGF-beta1, TGF-beta2, periostin and endothelin-1, by human airway e
209 largely determined by the aged environment, TGF-beta2 plays a major modulatory role that is subject
211 n combination with TNF-alpha, monocytes, and TGF-beta2 potently stimulated VEGF expression in hRPE ce
216 -beta2 was not explained by its geometry, as TGF-beta2 production was not inhibited by plating cells
218 diac fibroblasts through PI3K/AKT to produce TGF-beta2, promoting fibroblast-to-myofibroblast transfo
222 etween nasal and bronchial ALI production of TGF-beta2 (r = 0.64, P = .001) and VEGF (r = 0.73, P < .
223 K (-49.1 +/- 24.6%, n = 10, P = 0.0001), and TGF-beta2 receptor (-83.6 +/- 14.4%, n = 6, P = 0.003).
224 inase (p38), Smad3, p42, JNK, RhoA, PI3K, or TGF-beta2 receptor for 2 hours, and then TGF-beta2 was a
225 /6, thrombospondin-1 knockout (TSP-1KO), and TGF-beta2 receptor II double-negative (TGF-beta2 RII DN)
226 which the basement membrane was left intact, TGF-beta2 remained confined to the corneal epithelium, c
227 , and TGF-beta2 receptor II double-negative (TGF-beta2 RII DN) mice, leaving behind a healthy monolay
229 GF-beta- and BMP-reporter mice, we show that TGF-beta2 signaling antagonizes BMP signaling in HFSCs b
231 (TbetaRII-B), has been suggested to mediate TGF-beta2 signaling in the absence of TbetaRIII, we dire
232 tudy was to determine whether BMPs can alter TGF-beta2 signaling in the TM and whether there are defe
233 st that a loop between the Gas6/Axl axis and TGF-beta2 signaling plays a significant role in the indu
234 celerates anagen initiation, whereas loss of Tgf-beta2 signaling significantly delays it, supporting
235 ndogenous molecules in human TM may regulate TGF-beta2 signaling via inhibition of BMP family members
240 downregulation led to the inhibition of both TGF-beta2/Smad-dependent and -independent pathways, and
241 nd genetic studies unveil Tmeff1 as a direct TGF-beta2/Smad2/3 target gene, expressed by activated HF
251 Connective tissue growth factor (CTGF) is a TGF-beta2 target gene with high constitutive TM expressi
253 in the absence of TbetaRIII when sufficient TGF-beta2, TbetaRI, and TbetaRII or TbetaRII-B are prese
256 nscriptional activation of the gene encoding TGF-beta2 that acted in a paracrine manner on peritoneal
257 y-like tube formation insofar as adding back TGF-beta2 to infected cells blocks KSHV-induced long-ter
261 s (BMPs), which, coupled with the ability of TGF-beta2 to upregulate FST levels, may indicate a possi
264 ated in vitro by exposure to antigen-pulsed, TGF-beta2-treated APCs expressed genes related to immune
266 e end of the procedure, 10 microL TGF-beta2 (TGF-beta2-treated group), fetal calf serum (FCS)/phospha
267 a human monoclonal TGF-beta2 antibody (anti-TGF-beta2-treated group), or a null control IgG4 antibod
275 lts show that by blocking both TGF-beta1 and TGF-beta2 using neutralizing antibodies, it is possible
276 protein 2 (BMP-2) weakly or not at all, and TGF-beta2 variants with the corresponding residues from
277 plasmon resonance binding measurements with TGF-beta2 variants, we found that the BG(ZP-C)-binding s
279 om asthmatic children differentially express TGF-beta2, VEGF, ADAM33, or periostin compared with cell
280 om asthmatic children differentially express TGF-beta2, VEGF, and periostin compared with cells from
281 or TGF-beta2 receptor for 2 hours, and then TGF-beta2 was added for 24 hours in serum-free media.
283 ary epithelial cells stimulated by IL-17A or TGF-beta2 was also inhibited by 124.1% and 69.9%, respec
287 more, exogenous application of TGF-beta1 and TGF-beta2 was found to enhance c-JunSer-63 phosphorylati
288 titative trait locus (QTL) for the effect of TGF-beta2 was identified on chromosome 4 overlapping wit
290 In addition, Matrigel's ability to reduce TGF-beta2 was not explained by its geometry, as TGF-beta
293 oliferative effect of high concentrations of TGF-beta2, was abrogated, confirming the location of thi
295 imal amounts of free bioactive TGF-beta1 and TGF-beta2 were detected in conditioned medium, treatment
298 over a hitherto unrecognized DP transmitter, TGF-beta2, which activates Smad2/3 transiently in HFSCs
299 ut it may involve transforming growth factor TGF-beta2, which is found in higher amounts in the aqueo
300 Here, using NMR titrations of methyl-labeled TGF-beta2 with BG's C-terminal binding domain, BG(ZP-C),